The primary treatment for diabetes is blood glucose control; drugs that inhibit selective sodium–glucose cotransporter (SGLT1 and SGLT2; also known as SLC5A1 and SLC5A2) (ref. 1) hold great promise for reducing blood glucose levels. This evidence concerns the gene SLC5A2 and diabetes mellitus.